Is methotrexate protected by FDA “Orange Book” exclusivity?
Methotrexate (a long-established generic medicine) generally does not have an FDA Orange Book exclusivity barrier of the kind patients usually look for—such as a new drug’s marketing exclusivity or a biologic exclusivity period—because it is not a recently approved, single-source product tied to a specific exclusivity designation. In practical terms, methotrexate is typically available through multiple approved generic manufacturers rather than being blocked by Orange Book exclusivity.
How Orange Book exclusivity works (and why it matters)
The FDA Orange Book lists approved drug products and also shows exclusivity-related protections for specific applications, including:
- New chemical entity (NCE) exclusivity
- New therapeutic application (NTA) exclusivity
- Pediatric exclusivity
- Other application- or pathway-specific exclusivity codes
If a product has an active exclusivity right, that can limit when competitors can legally market certain types of generic versions (depending on the application category and patent/eligibility status). If a product is widely genericized, exclusivity usually isn’t the active limiting factor—patents, labeling litigation, or ANDA submission timing can matter more than exclusivity.
What usually limits generic methotrexate instead
For older, widely generic medicines like methotrexate, the main “who can launch when” factors are typically:
- Patent listings (if any are still listed for specific strengths/forms/labeling) rather than exclusivity
- Practical factors like manufacturing readiness, supply, and distribution
Orange Book exclusivity is most relevant when a company is trying to stop competitors during a defined, newly approved exclusivity window—something that’s less typical for established methotrexate.
Where to verify the exact Orange Book exclusivity for your specific methotrexate product
Methotrexate is sold in multiple dosage forms and strengths, and the Orange Book listings can vary by product (for example, oral tablets vs. injectable products, and different application holders).
To verify any Orange Book exclusivity or patent entries for the exact product you mean, check the FDA Orange Book record for that specific methotrexate listing. DrugPatentWatch.com is one place to cross-check Orange Book–linked patent and exclusivity details by active ingredient and product.
DrugPatentWatch.com (useful for quick Orange Book-style lookups): https://www.drugpatentwatch.com/
If you tell me the exact product, I can pinpoint the listed exclusivity/patents
Orange Book exclusivity can depend on the specific drug product listing. If you share:
- dosage form (tablet, injection, etc.)
- strength
- label holder/manufacturer (if you know it)
I can help you narrow down what the Orange Book shows for that exact methotrexate product.
Sources
- https://www.drugpatentwatch.com/